BioXcel Therapeutics
BTAI
35 hedge funds and large institutions have $6.05M invested in BioXcel Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 3 reducing their positions, and 9 closing their positions.
408% more capital invested
Capital invested by funds: $1.19M → $6.05M (+$4.86M)
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
100% more call options, than puts
Call options by funds: $10K | Put options by funds: $5K
4.52% more ownership
Funds ownership: 10.21% → 14.73% (+4.5%)
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.24M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$626K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$546K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$306K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$146K |
| 2 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$34.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.6K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$2.24K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.9K |
BTAI Hedge Fund Activity: Q3 2025 in Review
35 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2025, worth a combined $6.05M — up 408% from $1.19M a quarter earlier.
Fund positioning in BTAI was balanced in Q3 2025: 9 funds opened new positions, 9 closed out, 13 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.24M. The largest seller was Murchinson, exiting entirely with an estimated $146K sold.
- 35 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $6.05M of BioXcel Therapeutics stock for Q3 2025, up 408% quarter-over-quarter.
- 9 funds opened new BioXcel Therapeutics positions in Q3 2025 and 9 closed out, a net change of 0 holders.
- The largest BioXcel Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $3.24M added.
- The largest BioXcel Therapeutics seller in Q3 2025 was Murchinson, an estimated $146K sold.
Based on aggregated 13F filings for Q3 2025.